news
-
7 November 2019X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2019 and provided an update on recent developments in its business.
“Our core focus remains to advance our clinical programs with mavorixafor across our three lead rare disease indications. We are proud to report that we now have orphan drug designation in Europe, in addition to in the United States, for mavorixafor for treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome. We recently commenced enrollment in our pivotal Phase 3 clinical trial for the treatment of WHIM syndrome and are activating clinical sites globally. We have also now initiated the Phase 1b clinical trial in Severe Congenital Neutropenia. Preparations are underway for the initiation of the Phase 1b clinical trial in Waldenström’s macroglobulinemia later this quarter,” stated Paula Ragan, Ph.D., President and Chief Executive Officer of X4.
Related
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
X4 Pharmaceuticals Provides Business and Clinical Development Update
X4 Pharmaceuticals Completes Merger with Arsanis
Arsanis and X4 Pharmaceuticals Agree to Merger
Arsanis Reports Business Highlights and Financial Results for First Quarter 2018
Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies
Arsanis Announces Closing of Initial Public Offering
Arsanis Completes $45.5 Million Series D Financing
Arsanis Announces Two Key Publications Supporting Its Lead Program ASN100
Arsanis Inc Closes $20 Million Series B Financing